Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203380 | 1.00 | KDM4E (0.54) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL23832315 | 0.99 | KDM4E (0.55) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL29066902 | 0.96 | KDM4E (0.50) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL23845061 | 0.89 | TSHR (0.48) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL11615588 | 0.88 | TP53 (0.48) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL17938461 | 0.88 | DGKA (0.56) | ALDH1A1TSHRLMNAPAMDGKA | |
| SCHEMBL17938493 | 0.88 | DGKA (0.56) | ALDH1A1TSHRLMNAPAMDGKA | |
| SCHEMBL30525955 | 0.88 | DGKA (0.56) | ALDH1A1TSHRLMNAPAMDGKA | |
| SCHEMBL17938487 | 0.86 | CYP4F2 (0.54) | TSHRTP53CYP3A4MAPK1PAM | |
| SCHEMBL23844771 | 0.86 | MAPT (0.47) | KDM4EMEN1RECQLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-115605493-A | Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same | 吉利德科学公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021188959-A1 | PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | DCTD, MTAP, ADA | KDM4E 2522/4885MEN1 4076/4885RECQL 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.